<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Faricimab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Faricimab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Faricimab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="134932" href="/d/html/134932.html" rel="external">see "Faricimab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56563226"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vabysmo</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57121680"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Vabysmo</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56556511"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiopoietin-2 Inhibitor;</li>
<li>
                        Ophthalmic Agent;</li>
<li>
                        Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F56576812"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00dc0d3a-8e07-431d-8cf1-8d2a58a1c1bc">Age-related macular degeneration, neovascular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Age-related macular degeneration, neovascular (wet):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intravitreal:</b> Initial: 6 mg once every 4 weeks (approximately every 28 days) for 4 doses (Heier 2022; manufacturer's labeling). Subsequent doses are individualized based on visual assessments, and are administered as one of the following regimens:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Every-8-week regimen:</i> 6 mg on weeks 20, 28, 36, and 44 (Heier 2022; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Every-12-week regimen: </i>6 mg on weeks 24, 36, and 48 (Heier 2022; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Every-16-week regimen: </i>6 mg on weeks 28 and 44 (Heier 2022; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Additional efficacy was not demonstrated with dosing every 4 weeks throughout therapy; however, some patients may require dosing every 4 weeks following the initial 4 doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="867af98d-205e-460e-8955-a72b16570934">Diabetic macular edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic macular edema:</b> Doses may be administered based on one of the following regimens:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed interval regimen: </i>
<b>Intravitreal:</b> 6 mg once every 4 weeks (approximately every 28 days) for 6 doses, followed by 6 mg once every 8 weeks (Wykoff 2022; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Variable interval regimen: </i>
<b>Intravitreal:</b> 6 mg once every 4 weeks (approximately every 28 days) for at least 4 doses, followed by 6 mg every 4 to 16 weeks (based on visual assessments) (Wykoff 2022; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Additional efficacy was not demonstrated with dosing every 4 weeks throughout therapy; however, some patients may require dosing every 4 weeks following the initial 4 doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="536daf52-bb29-4d68-ada8-113232d4acb3">Macular edema following retinal vein occlusion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Macular edema following retinal vein occlusion:</b>
<b>Intravitreal:</b> 6 mg once every 4 weeks (approximately every 28 days) for 6 months.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F56576816"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥15 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F56576817"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F56576815"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56772550"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Ophthalmic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cataract</b>, <b>conjunctival hemorrhage</b>, <b>increased intraocular pressure</b> (IOP), <b>intraocular inflammation</b> (including <b>iridocyclitis</b>, <b>iritis</b>, <b>uveitis</b>, <b>vitritis</b>), <b>retinal pigment epithelium tear</b>, and<b> vitreous opacity </b>have been reported with faricimab use. <b>Conjunctival hyperemia</b>, <b>corneal abrasion</b>, <b>decreased visual acuity</b> (may be transient), <b>endophthalmitis</b>, <b>ocular hyperemia</b>, <b>rhegmatogenous retinal detachment</b>, <b>retinal hole without detachment</b>, retinal vasculitis, retinal vascular occlusion, <b>vitreous detachment</b>, and <b>vitreous hemorrhage </b>have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i></p>
<p style="text-indent:-2em;margin-left:6em;">IOP: Unknown; addition of fluid into the vitreous cavity may lead to transient increases in IOP. The mechanism for sustained increases in IOP is not well understood; proposed mechanisms include pharmacologic effect of vascular endothelial growth factor (VEGF) blockade, an anti-inflammatory mechanism/trabeculitis, impaired outflow due to protein aggregates/silicone droplet debris, and damage to outflow pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22990314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22990314'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:6em;">Rhegmatogenous retinal detachment: Unknown; possibly related to induction of posterior vitreous detachment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23722722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23722722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> IOP: Rapid; within 60 minutes of administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:0em;margin-left:4em;">Endophthalmitis:</p>
<p style="text-indent:-2em;margin-left:8em;">• Intravitreal injection posteriorly to the pars plana (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32034689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32034689'])">Ref</a></span>)</p>
<p style="text-indent:0em;margin-left:4em;">IOP:</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater number of intravitreal injections (VEGF inhibitor and/or steroid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22990314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22990314'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Personal or family history of glaucoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22990314','lexi-content-ref-32034689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22990314','lexi-content-ref-32034689'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thromboembolic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arterial thromboembolism</b>, including <b>acute myocardial infarction</b> and <b>cerebrovascular accident</b>, have been reported with faricimab use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Possibly due to systemic absorption of faricimab following intravitreal injection, leading to systemic vascular endothelial growth factor suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23722722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23722722'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56560122"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Cataract (≤15%)<span class="lexi-table-link-container"> (<a aria-label="Cataract table link" class="lexi-table-link" data-table-id="lexi-content-cataract" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cataract')">table 1</a>)</span><span class="table-link" style="display:none;">Cataract</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cataract" frame="border" id="lexi-content-cataract" rules="all">
<caption style="text-align:left;">
<b>Faricimab: Adverse Reaction: Cataract</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Aflibercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aflibercept)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diabetic macular edema</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,262</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">625</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Macular edema following retinal vein occlusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">641</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">635</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neovascular (wet) age-related macular degeneration</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">664</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">662</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thromboembolism (1% to 5%; including acute myocardial infarction and cerebrovascular accident)<span class="lexi-table-link-container"> (<a aria-label="Arterial Thromboembolism table link" class="lexi-table-link" data-table-id="lexi-content-arterial-thromboembolism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-arterial-thromboembolism')">table 2</a>)</span><span class="table-link" style="display:none;">Arterial Thromboembolism</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Arterial Thromboembolism" frame="border" id="lexi-content-arterial-thromboembolism" rules="all">
<caption style="text-align:center;">
<b>Faricimab: Adverse Reaction: Arterial Thromboembolism</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Aflibercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aflibercept)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diabetic macular edema</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,262</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">625</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neovascular (wet) age-related macular degeneration</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">664</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">662</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (8% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival hemorrhage (3% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Conjunctival Hemorrhage table link" class="lexi-table-link" data-table-id="lexi-content-conjunctival-hemorrhage" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-conjunctival-hemorrhage')">table 3</a>)</span><span class="table-link" style="display:none;">Conjunctival Hemorrhage</span>, eye discomfort (≤1%), eye irritation (≤1%), eye pain (≤3%), increased intraocular pressure (1% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Increased Intraocular Pressure table link" class="lexi-table-link" data-table-id="lexi-content-increased-intraocular-pressure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-intraocular-pressure')">table 4</a>)</span><span class="table-link" style="display:none;">Increased Intraocular Pressure</span>, increased lacrimation (1%), intraocular inflammation (1% to 2%; including iridocyclitis, iritis, uveitis, vitritis)<span class="lexi-table-link-container"> (<a aria-label="Intraocular Inflammation table link" class="lexi-table-link" data-table-id="lexi-content-intraocular-inflammation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-intraocular-inflammation')">table 5</a>)</span><span class="table-link" style="display:none;">Intraocular Inflammation</span>, retinal pigment epithelium tear (3%)<span class="lexi-table-link-container"> (<a aria-label="Retinal Pigment Epithelium Tear table link" class="lexi-table-link" data-table-id="lexi-content-retinal-pigment-epithelium-tear" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-retinal-pigment-epithelium-tear')">table 6</a>)</span><span class="table-link" style="display:none;">Retinal Pigment Epithelium Tear</span>, vitreous detachment (2% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Vitreous Detachment table link" class="lexi-table-link" data-table-id="lexi-content-vitreous-detachment" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vitreous-detachment')">table 7</a>)</span><span class="table-link" style="display:none;">Vitreous Detachment</span>, vitreous opacity (2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Vitreous Opacity table link" class="lexi-table-link" data-table-id="lexi-content-vitreous-opacity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vitreous-opacity')">table 8</a>)</span><span class="table-link" style="display:none;">Vitreous Opacity</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Conjunctival Hemorrhage" frame="border" id="lexi-content-conjunctival-hemorrhage" rules="all">
<caption style="text-align:center;">
<b>Faricimab: Adverse Reaction: Conjunctival Hemorrhage</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Aflibercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aflibercept)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diabetic macular edema</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,262</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">625</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Macular edema following retinal vein occlusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">641</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">635</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neovascular (wet) age-related macular degeneration</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">664</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">622</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Intraocular Pressure" frame="border" id="lexi-content-increased-intraocular-pressure" rules="all">
<caption style="text-align:center;">
<b>Faricimab: Adverse Reaction: Increased Intraocular Pressure</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Aflibercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aflibercept)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diabetic macular edema</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,262</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">625</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Macular edema following retinal vein occlusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">641</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">635</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neovascular (wet) age-related macular degeneration</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">664</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">622</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Intraocular Inflammation" frame="border" id="lexi-content-intraocular-inflammation" rules="all">
<caption style="text-align:center;">
<b>Faricimab: Adverse Reaction: Intraocular Inflammation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Aflibercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aflibercept)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diabetic macular edema</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,262</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">625</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Macular edema following retinal vein occlusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">641</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">635</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neovascular (wet) age-related macular degeneration</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">664</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">622</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Retinal Pigment Epithelium Tear" frame="border" id="lexi-content-retinal-pigment-epithelium-tear" rules="all">
<caption style="text-align:center;">
<b>Faricimab: Adverse Reaction: Retinal Pigment Epithelium Tear</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Aflibercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aflibercept)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neovascular (wet) age-related macular degeneration</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">664</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">622</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vitreous Detachment" frame="border" id="lexi-content-vitreous-detachment" rules="all">
<caption style="text-align:center;">
<b>Faricimab: Adverse Reaction: Vitreous Detachment</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Aflibercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aflibercept)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diabetic macular edema</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,262</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">625</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Macular edema following retinal vein occlusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">641</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">635</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neovascular (wet) age-related macular degeneration</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">664</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">622</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vitreous Opacity" frame="border" id="lexi-content-vitreous-opacity" rules="all">
<caption style="text-align:center;">
<b>Faricimab: Adverse Reaction: Vitreous Opacity</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Aflibercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Faricimab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aflibercept)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diabetic macular edema</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,262</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">625</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Macular edema following retinal vein occlusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">641</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">635</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neovascular (wet) age-related macular degeneration</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">664</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">622</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Ophthalmic: Blurred vision, conjunctival hyperemia, corneal abrasion, decreased visual acuity (may be transient), endophthalmitis, eye pruritus, foreign body sensation of eye, ocular hyperemia, retinal hole without detachment, rhegmatogenous retinal detachment, vitreous hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Ophthalmic: Retinal vascular disease (retinal vasculitis and retinal vascular occlusion)</p></div>
<div class="block coi drugH1Div" id="F56556514"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, rash, pruritus, urticaria, erythema, severe intraocular inflammation) to faricimab or any component of the formulation; ocular or periocular infections; active intraocular inflammation.</p></div>
<div class="block war drugH1Div" id="F56576789"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:0em;display:inline">There are no warnings listed in the manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F56563227"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vabysmo: Faricimab-svoa 6 mg/0.05 mL (120 mg/mL) (0.05 mL)</p></div>
<div class="block geq drugH1Div" id="F56563225"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56599693"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vabysmo Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/0.05 mL (per 0.05 mL): $2,628.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57121681"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vabysmo: Faricimab-svoa 6 mg/0.05 mL (120 mg/mL) (0.05 mL)</p></div>
<div class="block adm drugH1Div" id="F56576818"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intravitreal:</b> For ophthalmic intravitreal injection only. Administer under aseptic conditions. Allow vial to reach room temperature prior to administration. Each vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before faricimab is administered to the other eye. Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure. Refer to manufacturer's labeling for additional detailed information.</p></div>
<div class="block use drugH1Div" id="F56556513"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Age-related macular degeneration, wet (neovascular):</b> Treatment of neovascular (wet) age-related macular degeneration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic macular edema</b>
<b>:</b> Treatment of diabetic macular edema.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Macular edema:</b> Treatment of macular edema following retinal vein occlusion.</p></div>
<div class="block cyt drugH1Div" id="F56594652"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56594649"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F56576786"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action, faricimab may affect fertility. Patients who may become pregnant should use effective contraception during treatment and for at least 3 months after the last dose of faricimab.</p></div>
<div class="block pri drugH1Div" id="F56576787"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action, in utero exposure to faricimab may cause fetal harm. Faricimab is a vascular endothelial growth factor (VEGF) inhibitor; VEGF is required to achieve and maintain normal pregnancies (Peracha 2016; Petri 2020).</p></div>
<div class="block brc drugH1Div" id="F56576788"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if faricimab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F56576820"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure (via tonometry) and optic nerve head perfusion immediately following administration; symptoms of endophthalmitis and retinal detachment (eg, eye redness/pain, photophobia, blurred vision, other vision changes).</p></div>
<div class="block pha drugH1Div" id="F56576806"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Faricimab is a recombinant humanized bispecific antibody that inhibits vascular endothelial growth factor A (VEGF-A), resulting in suppression of endothelial cell proliferation, neovascularization, and vascular permeability. Faricimab also inhibits angiopoietin-2 (Ang-2), which promotes vascular stability and desensitizes blood vessels to effects of VEGF-A.</p></div>
<div class="block phk drugH1Div" id="F56576807"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Has not been fully characterized; expected to be catabolized in lysosomes to small peptides and amino acids.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~7.5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: ~2 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Has not been fully characterized; metabolites may be excreted renally.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847629"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Vabysmo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23722722">
<a name="23722722"></a>Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. <i>Eye (Lond)</i>. 2013;27(7):787-794. doi:10.1038/eye.2013.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/faricimab-drug-information/abstract-text/23722722/pubmed" id="23722722" target="_blank">23722722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35085502">
<a name="35085502"></a>Heier JS, Khanani AM, Quezada Ruiz C, et al; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. <i>Lancet</i>. 2022:S0140-6736(22)00010-1. doi:10.1016/S0140-6736(22)00010-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/faricimab-drug-information/abstract-text/35085502/pubmed" id="35085502" target="_blank">35085502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22990314">
<a name="22990314"></a>Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. <i>Retina</i>. 2013;33(1):179-187. doi:10.1097/IAE.0b013e318261a6f7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/faricimab-drug-information/abstract-text/22990314/pubmed" id="22990314" target="_blank">22990314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27388726">
<a name="27388726"></a>Peracha ZH, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy in pregnancy: what we know, what we don't know, and what we don't know we don't know. <i>Retina</i>. 2016;36(8):1413-1417. doi:10.1097/IAE.0000000000001200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/faricimab-drug-information/abstract-text/27388726/pubmed" id="27388726" target="_blank">27388726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32034689">
<a name="32034689"></a>Petri AS, Boysen K, Cehofski LJ, et al. Intravitreal injections with vascular endothelial growth factor inhibitors: a practical approach. <i>Ophthalmol</i>
<i>Ther</i>. 2020;9(1):191-203. doi:10.1007/s40123-020-00230-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/faricimab-drug-information/abstract-text/32034689/pubmed" id="32034689" target="_blank">32034689</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vabysmo (faricimab) [prescribing information]. South San Francisco, CA: Genentech Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35085503">
<a name="35085503"></a>Wykoff CC, Abreu F, Adamis AP, et al; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. <i>Lancet</i>. 2022:S0140-6736(22)00018-6. doi:10.1016/S0140-6736(22)00018-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/faricimab-drug-information/abstract-text/35085503/pubmed" id="35085503" target="_blank">35085503</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 134905 Version 39.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
